Acurx Pharmaceuticals (FRA:3ZO0) Marketable Securities: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3ZO0 Acurx Pharmaceuticals Inc FRA:3ZO0
37 GF Score
Price €5.09
View Full Analysis

What is Acurx Pharmaceuticals Marketable Securities?

Acurx Pharmaceuticals FRA:3ZO0 37 Marketable Securities is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:3ZO0 with a GF Score™ of 37/100.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Acurx Pharmaceuticals's Marketable Securities for the quarter that ended in Jun. 2026 was €0.00 Mil.

Acurx Pharmaceuticals  (FRA:3ZO0) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Acurx Pharmaceuticals Marketable Securities Related Terms

Acurx Pharmaceuticals Marketable Securities Historical Data

* Premium members only.

The historical data trend for Acurx Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acurx Pharmaceuticals Marketable Securities Chart

Acurx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Acurx Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:3ZO0
37GF Score
Acurx Pharmaceuticals Inc FRA:3ZO0
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acurx Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.00 Mil mean?
Acurx Pharmaceuticals (FRA:3ZO0) has a Marketable Securities of €0.00 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Acurx Pharmaceuticals and its competitors.
Is Acurx Pharmaceuticals' Marketable Securities too high?
Acurx Pharmaceuticals' current Marketable Securities is €0.00 Mil. Overall, Acurx Pharmaceuticals has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Acurx Pharmaceuticals' Marketable Securities compare to KAPA and PULM?
Acurx Pharmaceuticals' Marketable Securities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Acurx Pharmaceuticals and its competitors. Acurx Pharmaceuticals's current Marketable Securities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acurx Pharmaceuticals stock overvalued right now?
Acurx Pharmaceuticals (FRA:3ZO0) has a current Marketable Securities of €0.00 Mil. The current Marketable Securities is €0.00 Mil. Acurx Pharmaceuticals' overall GF Score™ is 37/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Acurx Pharmaceuticals (FRA:3ZO0), the current Marketable Securities is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acurx Pharmaceuticals Business Description

Other Exchanges ACXP:USA
Address 259 Liberty Avenue, Staten Island, NY, USA, 10305
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
37GF Score

Get the complete analysis for FRA:3ZO0

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.09
Price